Skip to main content
. Author manuscript; available in PMC: 2013 Feb 8.
Published in final edited form as: Sci Transl Med. 2012 Aug 8;4(146):146ra107. doi: 10.1126/scitranslmed.3004241

Fig. 2.

Fig. 2

Survival curve of NiV-infected subjects. Data from control subjects (n = 2) and sGHeV-vaccinated subjects (n = 9) were used to generate the Kaplan-Meier survival curve. Control included data from one additional historical control subject. Vaccinated subjects received 10, 50, or 100 μg of sGHeV administered subcutaneously twice. Average time to end-stage disease was 11 days in control subjects, whereas all vaccinated subjects survived until euthanasia at the end of the study.